Stock Analysis on Net

Allergan PLC (NYSE:AGN)

$22.49

This company has been moved to the archive! The financial data has not been updated since May 7, 2020.

Return on Equity (ROE)
since 2005

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Allergan PLC, ROE, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in thousands

The financial data reveals considerable variability in net income attributable to shareholders over the observed periods. Net income exhibits pronounced fluctuations, with positive earnings in some years contrasted by substantial losses in others. Notably, the company experienced a significant loss in 2006, followed by recovery and positive net income through 2007 to 2011. However, from 2012 onward, the trend shows an increase in the magnitude of losses, with particularly large negative net income figures in 2013, 2014, 2018, 2019, and 2020.

Shareholders’ equity demonstrates a generally upward trend, reflecting growth in the company’s net assets over time. Despite this overall increase, the equity value shows some volatility, with an especially sharp rise beginning in 2013, peaking around 2015 and 2016, followed by a gradual decline through 2019. This rising equity period coincides partially with years of fluctuating profitability, suggesting possible capital inflows or revaluations impacting equity levels beyond pure earnings retention.

Return on equity (ROE) mirrors the volatility of net income, fluctuating sharply throughout the timeline. Early years show modest positive returns, followed by a steep decline into negative territory in 2006, then a recovery to positive returns until 2011. Post-2011, ROE declines again, registering negative returns in several years, with a notable peak in 2016 indicating strong profitability relative to equity. However, the subsequent years return to negative figures, indicating diminished profitability and potential challenges in generating shareholder value.

Net Income (loss) Trends
Sharp volatility is evident with severe losses in several years and sporadic recoveries. Large losses are apparent from 2013 onwards, emphasizing unstable earnings performance.
Shareholders’ Equity Trends
Shares a general upward trajectory with a significant increase around mid-period, indicating asset growth or capital inflows despite erratic profitability.
Return on Equity (ROE) Trends
Follows the pattern of net income fluctuations, with positive peaks interspersed with notable negative returns, reflecting irregular profitability and inconsistent value generation for shareholders.
Overall Financial Insight
The data suggests the company experiences cyclical earnings challenges, with equity growth potentially bolstered by external factors. Profitability measures indicate difficulties in sustaining returns, necessitating further investigation into operational or market factors influencing financial stability.

Comparison to Competitors

Allergan PLC, ROE, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Allergan PLC, ROE, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)